Effects of Piracetam and Rivastigmine on Alzheimer's disease

INTERVENTION: Control group: placebo, capsule oral, once daily for 3 months. First group of intervention: Exelon, Capsule 1.5 mg oral, once daily for 3 months. Intervention 1: First group of intervention: Exelon, Capsule 1.5 mg oral, once daily for 3 months. Intervention 2: Control group: placebo, capsule oral, once daily for 3 months. Intervention 3: Second group of intervention: Piracetam, capsule 800 mg oral, once daily for 3 months. Intervention 4: Third group of intervention: Exelon, Capsule1.5 mg oral, once daily for 3 months and Piracetam, capsule 800 mg oral, once daily for 3 months. Placebo Second group of intervention: Piracetam, capsule 800 mg oral, once daily for 3 months. Third group of intervention: Exelon, Capsule1.5 mg oral, once daily for 3 months and Piracetam, capsule 800 mg oral, once daily for 3 months. Treatment ‐ Drugs CONDITION: Alzheimer. ; Dementia in Alzheimer's disease Dementia in Alzheimer's disease PRIMARY OUTCOME: Mini Mental Status Examination. Timepoint: beforthe intervention and 3 months after intervention. Method of measurement: Questionnaire. INCLUSION CRITERIA: INCLUSION CRITERIA: 1‐ age more than 40; 2‐ diagnosis of Alzheimer disease based on DSM‐IV criteria. Exclusion criteria: 1‐ history of consuming drugs (except for drugs used for controlling hypertension, heart ischemia, hyperlipidemia, diabetes); 2‐ history of other diseases; 3‐Allergy to Piracetam or Rivastigmine.